Eisai Co., Ltd. is taking the early lead on the US commercial effort for Leqembi (lecanemab) in Alzheimer’s disease, but the company’s partner,Biogen, Inc., will add reinforcement – as long as the drug has approval for reimbursement from the Centers for Medicare and Medicaid Services (CMS) following full approval by the US Food and Drug Administration.
“The starting gate is really CMS approval,” Biogen CEO Christopher Viehbacher said during the company’s first quarter sales and earnings...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
